Soluble receptor for advanced glycation end products (sRAGE) as a biomarker of COPD

Katherine A Pratte, Jeffrey L Curtis, Katerina Kechris, David Couper, Michael H Cho, Edwin K Silverman, Dawn L DeMeo, Frank C Sciurba, Yingze Zhang, Victor E Ortega, Wanda K O'Neal, Lucas A Gillenwater, David A Lynch, Eric A Hoffman, John D Newell, Alejandro P Comellas, Peter J Castaldi, Bruce E Miller, Simon D Pouwels, Nick H T Ten HackenRainer Bischoff, Frank Klont, Prescott G Woodruff, Robert Paine, R Graham Barr, John Hoidal, Claire M Doerschuk, Jean-Paul Charbonnier, Ruby Sung, Nicholas Locantore, John G Yonchuk, Sean Jacobson, Ruth Tal-Singer, Debbie Merrill, Russell P Bowler*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

19 Citations (Scopus)
38 Downloads (Pure)


BACKGROUND: Soluble receptor for advanced glycation end products (sRAGE) is a proposed emphysema and airflow obstruction biomarker; however, previous publications have shown inconsistent associations and only one study has investigate the association between sRAGE and emphysema. No cohorts have examined the association between sRAGE and progressive decline of lung function. There have also been no evaluation of assay compatibility, receiver operating characteristics, and little examination of the effect of genetic variability in non-white population. This manuscript addresses these deficiencies and introduces novel data from Pittsburgh COPD SCCOR and as well as novel work on airflow obstruction. A meta-analysis is used to quantify sRAGE associations with clinical phenotypes.

METHODS: sRAGE was measured in four independent longitudinal cohorts on different analytic assays: COPDGene (n = 1443); SPIROMICS (n = 1623); ECLIPSE (n = 2349); Pittsburgh COPD SCCOR (n = 399). We constructed adjusted linear mixed models to determine associations of sRAGE with baseline and follow up forced expiratory volume at one second (FEV1) and emphysema by quantitative high-resolution CT lung density at the 15th percentile (adjusted for total lung capacity).

RESULTS: Lower plasma or serum sRAGE values were associated with a COPD diagnosis (P < 0.001), reduced FEV1 (P < 0.001), and emphysema severity (P < 0.001). In an inverse-variance weighted meta-analysis, one SD lower log10-transformed sRAGE was associated with 105 ± 22 mL lower FEV1 and 4.14 ± 0.55 g/L lower adjusted lung density. After adjusting for covariates, lower sRAGE at baseline was associated with greater FEV1 decline and emphysema progression only in the ECLIPSE cohort. Non-Hispanic white subjects carrying the rs2070600 minor allele (A) and non-Hispanic African Americans carrying the rs2071288 minor allele (A) had lower sRAGE measurements compare to those with the major allele, but their emphysema-sRAGE regression slopes were similar.

CONCLUSIONS: Lower blood sRAGE is associated with more severe airflow obstruction and emphysema, but associations with progression are inconsistent in the cohorts analyzed. In these cohorts, genotype influenced sRAGE measurements and strengthened variance modelling. Thus, genotype should be included in sRAGE evaluations.

Original languageEnglish
Article number127
JournalRespiratory Research
Publication statusPublished - 27-Apr-2021

Cite this